Jade Biosciences JBIO 深 滬
等待開盤 10-28 09:30:00 美东时间
14.74
+0.240
+1.66%
華盛通- 最 高15.065
- 今 開14.52
- 成交量 65.29万股
- 最 低 14.355
- 昨 收 14.50
- 總市值 9.37亿
- 52周最高 28.00
- 市盈率 靜 --
- 換手率 1.03%
- 52周最低 8.825
- 委 比 -71.49%
- 總股本 6359.74万
- 歷史最高 1050.525
- 量 比 0.93
- 振 幅 4.90%
- 歷史最低 -40.25
- 每 手 1
- 風險率 4.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅94.81%！富瑞上调ArriVent BioPharma(AVBP)目标价至30美元，维持"买入"评级
今日重点评级关注：富瑞：维持ArriVent BioPharma"买入"评级，目标价从18美元升至30美元；古根海姆：维持第一太阳能"买入"评级，目标价从282美元升至299美元
今天 12:30
BTIG Reiterates Buy on Jade Biosciences, Maintains $77 Price Target
BTIG analyst Julian Harrison reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $77 price target.
10-27 17:45
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
Jade Biosciences announced at ASN Kidney Week 2026 that three posters on JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy, will be presented. The posters highlight the planned acceleration of the EVERGREEN Phase 3 trial, now expected to begin in Q4 2026, and interim data from the ongoing JUNIPER Phase 2 trial, anticipated in Q2 2027. The company expressed confidence in JADE101's potential to achieve sustained IgA reductions with qua...
10-21 11:00
美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $55 price target.
10-01 18:17
Jade Biosciences advances JADE301 toward Phase 1 trial
The latest announcement is out from Jade Biosciences ( ($JBIO) ). On September ...
09-30 19:28
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
JADE301, an investigational anti-IFN-β monoclonal antibody, has shown high-affinity, selective binding to IFN-β, potent inhibition of downstream signaling, and an extended half-life of approximately 25 days following subcutaneous administration in non-human primates. It demonstrated favorable tolerability and pharmacokinetic properties, supporting its potential as a best-in-class therapy for dermatomyositis (DM). A Phase 1 healthy volunteer trial...
09-30 11:00
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $47
Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises the price target from $45 to $47.
08-11 21:40
Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) Estimate
Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 11.63 percent increase over losses of $(0.86) per share from the same period last year.
08-10 19:08
